tiprankstipranks

Arcutis Biotherapeutics reports Q3 EPS (73c), consensus (91c)

Reports Q3 revenue $38.1M, consensus $26.95M. “We are very pleased with the performance this quarter, and believe we are well-positioned for continued strong net product revenue growth in the fourth quarter and to accelerate that momentum into 2024. We are on the cusp of a very significant expansion of the topical roflumilast opportunity during 2024 with the potential approvals and subsequent launches of topical roflumilast for seborrheic dermatitis and atopic dermatitis as well as expected further expansion of payer coverage,” said Frank Watanabe, President and CEO of Arcutis. “The Arcutis commercial team made significant progress in improving gross-to-net and laying the foundation for sustained growth during the quarter, and now, with Todd’s leadership and proven credentials in topical dermatology, we expect to further enhance our commercial execution.”

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on ARQT:

Disclaimer & DisclosureReport an Issue